Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 5/20 | 0.52 |
| ▸ | CA1 | P00915 | 5/20 | 0.52 |
| ▸ | CA2 | P00918 | 5/20 | 0.52 |
| ▸ | CA9 | Q16790 | 5/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MLYCD | O95822 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14158944 | 0.97 | ALDH1A1 (0.57) | TDP1ALDH1A1NPC1RAB9APOLB | |
| SCHEMBL29301875 | 0.94 | TDP1 (0.54) | TDP1ALDH1A1NPC1RAB9APOLB | |
| SCHEMBL14679108 | 0.94 | L3MBTL1 (0.61) | TDP1ALDH1A1NPC1RAB9APOLB | |
| SCHEMBL30905400 | 0.93 | POLB (0.67) | TDP1ALDH1A1NPC1RAB9APOLB | |
| SCHEMBL29780267 | 0.93 | ESRRG (0.53) | TDP1ALDH1A1NPC1RAB9APOLB | |
| SCHEMBL24412780 | 0.91 | HDAC6 (0.57) | TDP1ALDH1A1NPC1RAB9APOLB | |
| SCHEMBL22939550 | 0.91 | TDP1 (0.55) | TDP1ALDH1A1NPC1RAB9AMAOA | |
| SCHEMBL3904926 | 0.91 | TDP1 (0.55) | TDP1ALDH1A1NPC1RAB9AMAOA | |
| SCHEMBL17623598 | 0.91 | ALDH1A1 (0.51) | TDP1ALDH1A1NPC1RAB9APOLB | |
| SCHEMBL17623638 | 0.91 | ESRRG (0.57) | TDP1ALDH1A1NPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803804-B2 | Substituted pyrazines for use in the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-09-28 | — | — | US | disclosed |
| US-20080312217-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| EP-1968969-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007071396-A2 | PYRAZINOYLGUANIDINE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312217-A1 | Organic Compounds | TRPA1, TRPV1, CHRM1 | TDP1 2717/4885ALDH1A1 567/4885NPC1 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.